id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2006-E-0383-0007,FDA,FDA-2006-E-0383,"Notice of Final Determination from U.S. Patent and Trademark Office to Novo Nordisk, A/S",Other,Letter(s),2007-11-19T05:00:00Z,2007,11,,,2025-12-19T21:52:23Z,,0,0,09000064804603ab
FDA-2006-E-0383-0006,FDA,FDA-2006-E-0383,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2007-09-18T04:00:00Z,2007,9,,,2025-12-19T21:45:45Z,,0,0,09000064804603a9
FDA-2006-E-0383-0005,FDA,FDA-2006-E-0383,Determination of Regulatory Review Period for Purposes of Patent Extension; LEVEMIR,Notice,General Notice,2007-02-22T05:00:00Z,2007,2,2007-02-22T05:00:00Z,,2025-12-19T21:30:01Z,E7-3001,0,0,09000064804603a7
FDA-2006-E-0383-0004,FDA,FDA-2006-E-0383,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2007-02-07T05:00:00Z,2007,2,,,2025-12-19T21:26:49Z,,0,0,09000064804603a6
FDA-2006-E-0383-0003,FDA,FDA-2006-E-0383,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2007-01-16T05:00:00Z,2007,1,,,2025-12-19T21:24:57Z,,0,0,09000064804603a4
FDA-2006-E-0383-0002,FDA,FDA-2006-E-0383,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2006-08-17T04:00:00Z,2006,8,,,2025-12-19T21:22:52Z,,0,0,09000064804603a2
FDA-2006-E-0383-0001,FDA,FDA-2006-E-0383,Letter from U.S. Patent and Trademark to FDA CDER,Other,Letter(s),2006-06-16T04:00:00Z,2006,6,,,2025-12-19T21:12:37Z,,0,0,0900006480460370